ID29576A - Komposisi-komposisi mukoadesif cair oral - Google Patents

Komposisi-komposisi mukoadesif cair oral

Info

Publication number
ID29576A
ID29576A IDW20010449A ID20010449A ID29576A ID 29576 A ID29576 A ID 29576A ID W20010449 A IDW20010449 A ID W20010449A ID 20010449 A ID20010449 A ID 20010449A ID 29576 A ID29576 A ID 29576A
Authority
ID
Indonesia
Prior art keywords
composition
safe
mixtures
effective amount
respiratory tract
Prior art date
Application number
IDW20010449A
Other languages
English (en)
Indonesian (id)
Inventor
Douglas Joseph Dobrozsi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ID29576A publication Critical patent/ID29576A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Photolithography (AREA)
  • Cosmetics (AREA)
IDW20010449A 1998-08-24 1999-08-24 Komposisi-komposisi mukoadesif cair oral ID29576A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9757898P 1998-08-24 1998-08-24

Publications (1)

Publication Number Publication Date
ID29576A true ID29576A (id) 2001-09-06

Family

ID=22264129

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010449A ID29576A (id) 1998-08-24 1999-08-24 Komposisi-komposisi mukoadesif cair oral

Country Status (17)

Country Link
US (1) US6319513B1 (ja)
EP (1) EP1107733B1 (ja)
JP (1) JP2002523354A (ja)
KR (1) KR100413877B1 (ja)
CN (1) CN1195494C (ja)
AT (1) ATE300282T1 (ja)
AU (1) AU761968B2 (ja)
BR (1) BR9913178B1 (ja)
CA (1) CA2338704C (ja)
CO (1) CO5140082A1 (ja)
DE (1) DE69926377T2 (ja)
HU (1) HUP0103388A3 (ja)
ID (1) ID29576A (ja)
NO (1) NO20010832L (ja)
PE (1) PE20000862A1 (ja)
TR (1) TR200100628T2 (ja)
WO (1) WO2000010529A1 (ja)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223416B2 (en) * 1999-06-28 2007-05-29 Minu, L.L.C. Topical composition
EP1192933B1 (en) * 1999-07-02 2010-04-21 Mitsubishi Gas Chemical Company, Inc. Tooth bleaching compositions and method of bleaching discolored tooth
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
ATE316786T1 (de) * 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
US7927600B2 (en) * 2001-03-30 2011-04-19 Emile Loria Anti-allergic pharmaceutical composition containing at least one allergen and at least one antihistamine compound
FR2822709B1 (fr) * 2001-03-30 2007-01-19 Antialis Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique
US7179476B2 (en) * 2001-08-09 2007-02-20 Sekisui Chemical Co., Ltd. Medical composition for external use for dermatosis
CN1764432A (zh) * 2001-08-24 2006-04-26 明太古公司 用于治疗或预防细菌感染和真茵感染的漱口剂
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
DK1474109T3 (da) 2001-12-21 2010-10-25 Alcon Inc Anvendelse af syntetiske uorganiske nanopartikler som bærere af ophthalmiske lægemidler
ATE486587T1 (de) * 2002-01-15 2010-11-15 Ucb Farchim Sa Formulierungen zur oralen verabreichung von wirkstoffen
BG65734B1 (bg) * 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
EP1496867A1 (en) * 2002-04-08 2005-01-19 Lavipharm Laboratories, Inc. Drug-complex microparticles and methods of making/using same
MXPA04009979A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
AU2003229771A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
JP4500261B2 (ja) 2003-01-21 2010-07-14 千寿製薬株式会社 ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性液剤
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050154343A1 (en) * 2004-01-14 2005-07-14 Mohinder Singh Soft tip applicator for relieving mouth pain
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7482378B2 (en) * 2004-05-28 2009-01-27 Millenium Specialty Chemicals, Inc. Physiological cooling compositions
WO2006020190A1 (en) * 2004-07-16 2006-02-23 Richard Plymale Dentifrice composition
WO2006026337A1 (en) * 2004-08-25 2006-03-09 Fairfield Clinical Trials, Llc Combination of a proton pump inhibitor and a h2 antagonist for the treatment of gastroesophageal reflux disease
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
NZ555501A (en) 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20060210482A1 (en) * 2005-03-18 2006-09-21 John Cassara Chemical composition and method for cold and sinus relief
US7985743B1 (en) * 2005-07-22 2011-07-26 Gene A. Tabish Topical pain reliever and method of making the same
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
EP2037916A4 (en) * 2006-04-07 2011-09-14 Mike Nicolaou PURE TRITOQUALINE ISOMERS
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
EP2170317A4 (en) * 2007-02-12 2011-03-23 Mike Nicolaou TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
AU2014201068B2 (en) * 2007-06-08 2016-07-07 The Procter & Gamble Company Natural honey-containing compositions and method of preparation
PL2002733T3 (pl) * 2007-06-08 2017-06-30 The Procter And Gamble Company Kompozycja zawierająca miód naturalny i sposoby jej sporządzania
ITMI20071623A1 (it) 2007-08-03 2009-02-04 Vetagro S R L Composizione sinergica comprendente sostanze aromatizzanti ed acidi organici, e relativo uso
ES2729925T3 (es) 2007-11-13 2019-11-07 Meritage Pharma Inc Composiciones de corticosteroides
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
GB0807621D0 (en) * 2008-04-25 2008-06-04 Ineos Healthcare Ltd Use
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8361519B2 (en) 2010-11-18 2013-01-29 Aadvantics Pharmaceuticals, Inc. Combination herbal product to benefit respiratory tract in people exposed to smoke
US20140213644A1 (en) * 2010-12-30 2014-07-31 Ziv Harish Formulations and Methods for Prevention and Treatment of Oral Allergy Syndrome
CN104812373B (zh) * 2012-12-06 2019-01-08 高露洁-棕榄公司 用于敏感性和牙齿疼痛的口用凝胶
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CN108430922B (zh) * 2015-12-30 2020-05-08 高露洁-棕榄公司 用于细菌聚集的粘蛋白包被的二氧化硅
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US10583081B1 (en) * 2017-11-27 2020-03-10 Richard A. Myers Apparatus and formulation for treating mouth ulcers
JP7497289B2 (ja) 2018-01-09 2024-06-10 ドンペ ファーマシューティシ エス．ピー．エー． 成長因子耳用製剤
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
US20210244710A1 (en) * 2018-07-02 2021-08-12 Kangping Xiao Stable pharmaceutical formulations of oxymetazoline
WO2020053609A1 (en) 2018-09-11 2020-03-19 Lead Biotherapeutics Ltd. Mucoadhesive dispersion nanoparticle system and method for production the same
EP3965886A4 (en) * 2019-02-15 2023-06-07 Ferrer Medical Innovations, LLC NASAL SPRAY COMPOSITIONS AND RELATED METHODS OF TREATMENT

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352752A (en) 1963-07-25 1967-11-14 Tintex Corp Intestinal adsorbent compositions
JPS589083B2 (ja) 1975-05-30 1983-02-18 武田薬品工業株式会社 シヨウリユウザイノセイゾウホウ
FR2346017A1 (fr) 1975-10-23 1977-10-28 Rech Applic Scient Composition therapeutique pour le traitement des affections du tractus gastro-intestinal
FR2502956A1 (fr) * 1981-04-01 1982-10-08 Human Pharm Sa Laboratoires Composition therapeutique utile comme topique digestif
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS61106509A (ja) * 1984-10-29 1986-05-24 Fujisawa Pharmaceut Co Ltd 鼻腔用医薬組成物
AU594765B2 (en) 1986-05-16 1990-03-15 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparations for applications on esophagus mucosa
US5464828A (en) 1988-03-02 1995-11-07 Chugai Pharmaceutical Co., Ltd. Aqueous suspension of sucralfate
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
WO1991006289A1 (en) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
JPH0639368B2 (ja) 1990-02-28 1994-05-25 株式会社萩原技研 シリカゲルを母体とした抗菌性組生物
GB9025710D0 (en) 1990-11-27 1991-01-09 Beecham Group Plc Novel treatment
EP0517274A1 (de) 1991-06-07 1992-12-09 Byk Nederland BV Pharmazeutische Klistierzubereitung
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JPH0725769A (ja) * 1992-10-20 1995-01-27 Fuji Chem Ind Co Ltd アロプリノール医薬用液剤ならびにその製造法
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5554379A (en) 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5670163A (en) 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
JP3927253B2 (ja) * 1995-02-02 2007-06-06 中外製薬株式会社 スクラルファート製剤
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
FR2739558B1 (fr) 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale

Also Published As

Publication number Publication date
CA2338704A1 (en) 2000-03-02
DE69926377D1 (de) 2005-09-01
KR100413877B1 (ko) 2004-01-07
AU761968B2 (en) 2003-06-12
CO5140082A1 (es) 2002-03-22
HUP0103388A2 (hu) 2002-01-28
PE20000862A1 (es) 2000-09-13
HUP0103388A3 (en) 2006-02-28
CN1195494C (zh) 2005-04-06
CA2338704C (en) 2004-11-02
KR20010072678A (ko) 2001-07-31
NO20010832D0 (no) 2001-02-19
CN1313756A (zh) 2001-09-19
BR9913178B1 (pt) 2014-11-25
ATE300282T1 (de) 2005-08-15
EP1107733B1 (en) 2005-07-27
BR9913178A (pt) 2001-05-15
NO20010832L (no) 2001-02-19
AU5580999A (en) 2000-03-14
JP2002523354A (ja) 2002-07-30
DE69926377T2 (de) 2006-06-01
US6319513B1 (en) 2001-11-20
EP1107733A1 (en) 2001-06-20
TR200100628T2 (tr) 2001-10-22
WO2000010529A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
ID29576A (id) Komposisi-komposisi mukoadesif cair oral
ATE227978T1 (de) Orale flüssige mucoadhäsive zusammensetzungen
JPH0161086B2 (ja)
JPH03197430A (ja) 呼吸器管感染症用スプレー剤
WO1999059544A3 (en) Orally disintegrable tablets
CA2321819A1 (en) Xylitol compositions for treating upper respiratory conditions
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
JP2004525903A5 (ja)
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
WO2003015746A1 (en) Nasal passage cleaning composition
DE69903651D1 (de) Orale flüssige mucoadhäsive zusammensetzungen
WO2001012128A3 (en) Antibacterial agents for the treatment of acute mucosal infections
JP2001139465A (ja) 咽頭粘膜用組成物
JP2007022971A (ja) 経鼻投与のための組成物
JP2002145764A (ja) 咽頭粘膜用組成物
RU2001126302A (ru) Способ терапевтического или профилактического лечения стрептококковых инфекций (варианты) и композиция, предназначенная для использования в нем (варианты), лизин, ассоциированный с фагом стрептококков группы C, - активный агент фармацевтической композиции
BR0205625C1 (pt) Formulações nasais em gel